Top Markets
Coin of the day
Marizyme, Inc. Marizyme, Inc.

Marizyme, Inc.

MRZM
주식 순위 #41138
Marizyme, Inc. is a life sciences company primarily engaged in bringing... Marizyme, Inc. is a life sciences company primarily engaged in bringing innovative medical technologies from development to market. Its offerings include DuraGraft, a unique single-application treatment administered during vascular and bypass surgeries, engineered to maintain the function and structure of the endothelium, along with other critical characteristics. The company is also progressing with various therapeutic products utilizing its Krillase protease-based platform. These are being developed to address conditions such as severe wounds and burns, acute ischemic stroke, deep vein thrombosis, and for the removal of dental plaque and biofilms. Additionally, Marizyme focuses on creating solutions to mitigate the damaging effects of ischemia-reperfusion injury in different grafting and organ transplantation procedures, among other medical applications. A further key initiative is the development of MATLOC, a digital, point-of-care, lab-on-chip device platform designed for the screening and diagnosis of chronic kidney disease. Established in 2007, Marizyme, Inc., previously known as GBS Enterprises Incorporated, is headquartered in Jupiter, Florida.
주가
$0.0003
마지막 동기화: 2026-08-12
시가총액
$39.54K
변동 (1일)
0.00%
변동 (1년)
0.00%
국가
US
거래 Marizyme, Inc. (MRZM)

카테고리

Marizyme, Inc. (MRZM)의 배당 수익률 기록
Marizyme, Inc. (주식 심볼: MRZM)의 배당 수익률 (TTM)은 2026 기준으로 0입니다.
지난 5년 평균 배당 수익률: 0.00%
Marizyme, Inc. (MRZM)의 배당 수익률 기록: 2026 ~ 2026
연도별 말 기준 배당 수익률 (TTM)
연도 배당 수익률 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 배당 수익률 (TTM)